BG103957A - Паратиреоиден хормон - Google Patents

Паратиреоиден хормон Download PDF

Info

Publication number
BG103957A
BG103957A BG103957A BG10395799A BG103957A BG 103957 A BG103957 A BG 103957A BG 103957 A BG103957 A BG 103957A BG 10395799 A BG10395799 A BG 10395799A BG 103957 A BG103957 A BG 103957A
Authority
BG
Bulgaria
Prior art keywords
seq
lys
fmoc
asp
nle
Prior art date
Application number
BG103957A
Other languages
Bulgarian (bg)
English (en)
Inventor
Stephen Condon
Isabelle Morize
Original Assignee
Aventis Pharmaceuticals Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharmaceuticals Inc. filed Critical Aventis Pharmaceuticals Inc.
Publication of BG103957A publication Critical patent/BG103957A/bg

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/18Drugs for disorders of the endocrine system of the parathyroid hormones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/635Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BG103957A 1997-05-14 1999-12-06 Паратиреоиден хормон BG103957A (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4647297P 1997-05-14 1997-05-14
PCT/US1998/009843 WO1998051324A1 (en) 1997-05-14 1998-05-13 Peptide parathyroid hormone analogs

Publications (1)

Publication Number Publication Date
BG103957A true BG103957A (bg) 2000-04-28

Family

ID=21943653

Family Applications (1)

Application Number Title Priority Date Filing Date
BG103957A BG103957A (bg) 1997-05-14 1999-12-06 Паратиреоиден хормон

Country Status (20)

Country Link
US (2) US6472505B1 (ko)
EP (1) EP0986395A4 (ko)
JP (1) JP2001517957A (ko)
KR (1) KR100351213B1 (ko)
CN (1) CN1261281A (ko)
AP (1) AP9901686A0 (ko)
AU (1) AU746461B2 (ko)
BG (1) BG103957A (ko)
BR (1) BR9808786A (ko)
CA (1) CA2290443A1 (ko)
EA (1) EA002819B1 (ko)
HU (1) HUP0003349A3 (ko)
IL (1) IL132901A0 (ko)
NO (1) NO995568L (ko)
OA (1) OA11216A (ko)
PL (1) PL336803A1 (ko)
SK (1) SK151599A3 (ko)
UA (1) UA62967C2 (ko)
WO (1) WO1998051324A1 (ko)
ZA (1) ZA984077B (ko)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002511483A (ja) * 1998-04-15 2002-04-16 アヴェンティス ファーマシューティカルズ プロダクツ インコーポレイテッド 樹脂結合環状ペプチドの製造方法
US6316410B1 (en) 1999-09-22 2001-11-13 National Research Council Of Canada Parathyroid hormone analogues for the treatment of osteoporosis
AU2003233286A1 (en) * 2002-05-16 2003-12-02 Theratechnologies Inc. Pth derivatives resistant to skin proteases
WO2004073587A2 (en) * 2003-02-19 2004-09-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with parathyroid hormone receptor 1 (pthr1)
EP1644017A2 (en) * 2003-07-15 2006-04-12 National Research Council Of Canada Cyclic analogs of human parathyroid hormone for the treatment of conditions characterized by hyperproliferative skin cells
US7439226B2 (en) * 2003-09-30 2008-10-21 The United States Of America As Represented By The Department Of Health And Human Services Serine protease inhibitors
US20060052305A1 (en) * 2004-05-10 2006-03-09 Nastech Pharmaceutical Company Inc. Method of treating osteoporosis using intranasal parathyroid hormone
US20060127320A1 (en) * 2004-05-10 2006-06-15 Nastech Pharmaceutical Company Inc. Method of delivering parathyroid hormone to a human
US20060052306A1 (en) * 2004-05-10 2006-03-09 Nastech Pharmaceutical Company Inc. GRAS composition for enhanced mucosal delivery of parathyroid hormone
JP2007537274A (ja) * 2004-05-10 2007-12-20 ナステック ファーマスーティカル カンパニー インク. 副甲状腺ホルモンの粘膜送達を増強するための組成物及び方法
US9051379B2 (en) 2005-07-07 2015-06-09 Fulcrum Sp Ltd. Sp1 polypeptides, modified Sp1 polypeptides and uses thereof
US20070173447A1 (en) * 2005-10-25 2007-07-26 Nastech Pharmaceutical Company Inc. Method for treating osteoporosis by intranasal delivery of teriparatide with an anti-resorptive agent
CN101355959B (zh) * 2005-11-10 2013-02-27 密歇根理工大学管理委员会 黑熊甲状旁腺素和使用黑熊甲状旁腺素的方法
US20080051332A1 (en) * 2005-11-18 2008-02-28 Nastech Pharmaceutical Company Inc. Method of modulating hematopoietic stem cells and treating hematologic diseases using intranasal parathyroid hormone
WO2008048784A1 (en) * 2006-10-13 2008-04-24 Eli Lilly And Company Pegylated pth as pth receptor modulators and uses thereof
WO2010086867A2 (en) 2009-02-02 2010-08-05 Ramot At Tel Aviv University Ltd. Peptides, pharmaceutical compositions comprising same and uses thereof
CA2759201A1 (en) 2009-04-01 2010-10-07 The Medical Research, Infrastructure, And Health Services Fund Of The Te L Aviv Medical Center A method of regulating proliferation and differentiation of keratinocyes
WO2010116375A1 (en) 2009-04-08 2010-10-14 Yeda Research And Development Co. Ltd. Isolated peptides for regulating apoptosis
US20120070449A1 (en) 2009-05-28 2012-03-22 Yeda Research And Development Co. Ltd. Methods of treating inflammation
PT2459208T (pt) * 2009-07-29 2017-01-03 Kai Pharmaceuticals Inc Agentes terapêuticos para redução dos niveis de hormona paratiroideia
CA2782640A1 (en) 2009-12-07 2011-06-16 Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
EP2566500B1 (en) 2010-05-05 2017-04-12 Rappaport Family Institute for Research in the Medical Sciences Ccl1 for use in therapy
JP5941040B2 (ja) * 2010-05-13 2016-06-29 ザ ジェネラル ホスピタル コーポレイション 副甲状腺ホルモン類似体およびその使用
WO2012017439A2 (en) 2010-08-04 2012-02-09 Ramot At Tel-Aviv University Ltd. Methods of treating autoimmune diseases of the central nervous system (cns) and neurodegenerative diseases
WO2012131680A2 (en) 2011-03-28 2012-10-04 Yeda Research And Development Co. Ltd. Compositions and methods for treating inflammation
US8741491B2 (en) * 2011-06-17 2014-06-03 Fluidic, Inc. Ionic liquid containing sulfonate ions
KR101912982B1 (ko) 2012-03-06 2018-10-29 셀렉트 바이오테라퓨틱스 리미티드 세포자멸사-신호전달 내성 세포를 선택하기 위한 디바이스 및 방법, 그리고 그의 용도
ES2717446T3 (es) 2013-09-17 2019-06-21 Yeda Res & Dev Péptidos derivados de ERK y usos de los mismos
WO2015114633A1 (en) 2014-01-30 2015-08-06 Yissum Research And Development Company Of The Hebrew University Of Jerusalem Ltd. Actin binding peptides and compositions comprising same for inhibiting angiogenes is and treating medical conditions associated with same
US20170174764A1 (en) 2014-03-27 2017-06-22 Yeda Research And Development Co. Ltd. T-cell receptor cdr3 peptides and antibodies
EP3261582B1 (en) 2015-02-26 2021-01-06 Remodeless CV Ltd. Methods and compositions relating to leptin antagonists
KR20210089270A (ko) 2015-07-16 2021-07-15 바이오카인 테라퓨틱스 리미티드 암 치료용 조성물 및 방법
WO2017122209A2 (en) 2016-01-12 2017-07-20 Yeda Research And Development Co. Ltd. NF-kappaB INHIBITORS
IL243838A (en) 2016-01-28 2017-07-31 Sp Nano Ltd The composition containing sp1 protein and carbon nanoparticles and its uses
IL243839B (en) 2016-01-28 2018-01-31 Sp Nano Ltd Conductive wires
EP3464322B1 (en) 2016-06-05 2023-04-05 Tel HaShomer Medical Research Infrastructure and Services Ltd. Novel molecules for the treatment of inflammation
WO2018037416A1 (en) 2016-08-25 2018-03-01 Yeda Research And Development Co. Ltd. Methods and compositions for treating autoimmune diseases
MX2018016003A (es) 2016-12-01 2019-05-16 Univ Ramot Tratamiento combinado para lesiones neurológicas.
EA201992400A1 (ru) 2017-04-07 2020-04-16 Йисум Рисёч Девелопмент Кампани Оф Зэ Хибру Юниверсити Оф Джерузалем Лтд. Композиции для ухода за волосами
WO2018216011A1 (en) 2017-05-23 2018-11-29 Technion Research & Development Foundation Limited Agents which inhibit gads dimerization and methods of use thereof
WO2019016819A1 (en) 2017-07-20 2019-01-24 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. NANOPARTICLE COMPOSITIONS
IL253642A0 (en) 2017-07-24 2017-09-28 Seger Rony Combined treatment for cancer
IL253984A0 (en) 2017-08-14 2017-09-28 Yeda Res & Dev Immunotherapy against aranviruses that bind through transferrin receptor 1 (tfr1
IL274979B1 (en) 2017-11-29 2024-03-01 Univ Ramot Methods for the prevention and treatment of neurogenic seizures
US20210214417A1 (en) 2018-07-11 2021-07-15 Kahr Medical Ltd. SIRPalpha-4-1BBL VARIANT FUSION PROTEIN AND METHODS OF USE THEREOF
IL265486A (en) 2019-03-19 2020-09-30 Yeda Res & Dev Bistable type ii opsins and uses thereof
IL266728B (en) 2019-05-19 2020-11-30 Yeda Res & Dev Identification of recurrent mutant neopeptides
CA3146248A1 (en) 2019-07-11 2021-01-14 Kahr Medical Ltd. Heterodimers and methods of use thereof
IL268111A (en) 2019-07-16 2021-01-31 Fainzilber Michael Methods of treating pain
IL270800A (en) 2019-11-20 2021-05-31 Yeda Res & Dev A method for treating Alzheimer's disease
CA3170374A1 (en) 2020-02-09 2021-08-12 Nlc Pharma Ltd Rapid detection test for sars-cov-2
WO2021176457A1 (en) 2020-03-05 2021-09-10 Ariel Scientific Innovations Ltd. Anti-hemorrhaging compositions
EP4121441A1 (en) 2020-03-16 2023-01-25 Yeda Research and Development Co. Ltd Peptide analogs and use of same in treating diseases, disorders or conditions associated with a mutant p53 protein
IL276599A (en) 2020-08-09 2022-03-01 Yeda Res & Dev T cell receptor unique to mage-a1 and its uses
IL276627A (en) 2020-08-10 2022-03-01 Yeda Res & Dev Compositions for diagnosis and treatment of coronavirus infections
IL301503A (en) 2020-09-23 2023-05-01 Yeda res & development co ltd Methods and preparations for the treatment of the disease caused by the corona virus
JP2023545740A (ja) 2020-10-07 2023-10-31 プロタリクス リミテッド 長期活性DNase
JP2023548496A (ja) 2020-11-03 2023-11-17 プロタリクス リミテッド 修飾ウリカーゼ及びその使用
CA3208982A1 (en) 2021-02-18 2022-08-25 Ravid STRAUSSMAN Method of generating vaccines
IL283563A (en) 2021-05-30 2022-12-01 Yeda Res & Dev Profiling of amps for the diagnosis, monitoring and treatment of microbiome-related diseases
WO2023031934A1 (en) 2021-09-02 2023-03-09 Yeda Research And Development Co. Ltd. Agents that target the glycine arginine-rich domain of nucleolin and uses thereof
WO2024038462A1 (en) 2022-08-17 2024-02-22 Yeda Research And Development Co. Ltd. Novel bacteria-based delivery system for tace (adam17) selective biological inhibitor

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4086196A (en) * 1975-03-28 1978-04-25 Armour Pharmaceutical Company Parathyroid hormone
US4423037A (en) 1982-05-13 1983-12-27 The General Hospital Corporation Inhibitors of peptide hormone action
US4427827A (en) 1982-10-20 1984-01-24 Usv Pharmaceutical Corporation Synthesis of hormone fragments
FR2550204B1 (fr) * 1983-08-05 1987-11-13 Toyo Jozo Kk Derives peptidiques de (nle8,nle1b, tyr34)-h-pth
US4771124A (en) 1987-05-26 1988-09-13 Merck & Co., Inc. Parathyroid hormone antagonists with simplified synthetic methodology
CA2040264A1 (en) 1990-04-12 1991-10-13 Tatsuhiko Kanmera Parathyroid hormone antagonists
CA2087087C (en) 1992-01-22 2000-07-18 Burton H. Sage, Jr. Molecules for iontophoretic delivery
US5434246A (en) 1992-03-19 1995-07-18 Takeda Chemical Industries, Ltd. Parathyroid hormone derivatives
US5814603A (en) 1992-06-12 1998-09-29 Affymax Technologies N.V. Compounds with PTH activity
CA2098639A1 (en) 1992-06-19 1993-12-20 K. Anne Kronis Bone stimulating, non-vasoactive parathyroid hormone variants
US5589452A (en) 1992-07-14 1996-12-31 Syntex (U.S.A.) Inc. Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis
AU672790B2 (en) 1992-07-15 1996-10-17 Novartis Ag Variants of parathyroid hormone and its fragments
EP0679088B1 (en) 1992-09-29 2002-07-10 Inhale Therapeutic Systems Pulmonary delivery of active fragments of parathyroid hormone
US5556940A (en) 1994-06-20 1996-09-17 National Research Council Of Canada Parathyroid hormone analogues for the treatment of osteoporosis
CO4410206A1 (es) 1994-07-28 1997-01-09 Sandoz Ag DERIVADOS DE PTH o PTHrP, SU PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LAS COMPRENDEN
DE19508672A1 (de) * 1995-03-10 1996-09-12 Boehringer Mannheim Gmbh Neue cyclische Parathormonfragmente, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
EP0747817B1 (en) 1995-06-07 2003-09-03 Compaq Computer Corporation Method and apparatus for controlling data communication flow in a fault-tolerant multiprocessor system
US5717062A (en) * 1995-06-07 1998-02-10 Beth Israel Hospital Association Cyclic analogs of PTH and PTHrP
US5723577A (en) 1995-07-13 1998-03-03 Biomeasure Inc. Analogs of parathyroid hormone
DE69725850T2 (de) * 1996-08-02 2004-08-19 National Research Council Of Canada, Ottawa Analoge des parathormons zur behandlung der osteoporose

Also Published As

Publication number Publication date
US6472505B1 (en) 2002-10-29
IL132901A0 (en) 2001-03-19
AP9901686A0 (en) 1999-12-31
JP2001517957A (ja) 2001-10-09
HUP0003349A3 (en) 2001-12-28
NO995568D0 (no) 1999-11-12
PL336803A1 (en) 2000-07-17
AU7386798A (en) 1998-12-08
EA199901025A1 (ru) 2000-06-26
SK151599A3 (en) 2000-09-12
HUP0003349A2 (hu) 2001-01-29
UA62967C2 (en) 2004-01-15
EP0986395A1 (en) 2000-03-22
EA002819B1 (ru) 2002-10-31
KR100351213B1 (ko) 2002-09-05
CN1261281A (zh) 2000-07-26
US20020132973A1 (en) 2002-09-19
BR9808786A (pt) 2000-07-11
EP0986395A4 (en) 2004-12-01
ZA984077B (en) 1998-11-24
AU746461B2 (en) 2002-05-02
CA2290443A1 (en) 1998-11-19
WO1998051324A1 (en) 1998-11-19
NO995568L (no) 1999-12-29
KR20010012568A (ko) 2001-02-15
OA11216A (en) 2003-07-10

Similar Documents

Publication Publication Date Title
BG103957A (bg) Паратиреоиден хормон
TWI250990B (en) Melanocortin receptor ligands
JP6220180B2 (ja) 合成ペプチドアミドおよびその二量体
JP5244810B2 (ja) 合成ペプチドアミド
EP0315367B1 (en) Polypeptides
AU636301B2 (en) Cyclic grf-analogs ii
SK15352000A3 (sk) Spôsob výroby cyklických peptidov viazaných k polymérnemu nosiču
JP2013542211A (ja) グルコース依存性インスリン分泌促進ペプチド類似体
JP2007535466A (ja) ラクタム架橋を有する、コンホメーションが制限された副甲状腺ホルモン(pth)アナログ
KR102117216B1 (ko) 강력한 작용제 효과를 지닌 신규한 gh-rh 유사체
CN104822702A (zh) α-MSH和γ-MSH类似物
JP5744844B2 (ja) 副甲状腺ホルモン(pth)受容体アゴニストとしての短鎖ペプチド
US20040122013A1 (en) Analogs of nocicettin
JP2002502381A (ja) 環状crfアンタゴニストペプチド
JPS61210099A (ja) 新規な成長ホルモン放出性ペプチド
JPH07316195A (ja) 新規なPTHrP関連ペプチド及びその用途
JP2001505216A (ja) ブラジキニンb▲下2▼レセプターのペプチドアゴニスト
NZ226178A (en) Linear and cyclic analogues of growth hormone releasing factor and pharmaceutical compositions
CA2405724C (en) Substance p analogs for the treatment of cancer
JP5529014B2 (ja) 部位特異的なペグ化をされた直鎖状のサケカルシトニン類似体
MXPA99010560A (en) Detergent compositions
JP2513440B2 (ja) 新規ペプチド
WO2014075137A1 (en) Peptides incorporating amino-substituted lactams for treatment of retinopathy
MXPA99010562A (en) Peptide parathyroid hormone analogs
CZ9904022A3 (cs) Peptidové analogy parathyroidálního hormonu